Alterras Therapeutics

Alterras Therapeutics is an early-stage biotechnology company focused on the discovery and development of next-generation therapies for complement-mediated diseases. The company utilizes a precision medicine approach to target specific components of the complement system, a part of the innate immune system that, when dysregulated, drives various inflammatory and autoimmune conditions. Founded by industry veterans and backed by prominent venture capital firms such as ARCH Venture Partners and F-Prime Capital, Alterras is primarily focused on developing oral small molecule inhibitors. These candidates are designed to provide more convenient and potentially more effective alternatives to current injectable standards of care. The company is currently advancing its lead programs through preclinical development toward initial clinical trials.